Psilocybin & Ibogaine: Can Psychedelics Cure Addiction?

Overview

The video explores whether psychedelic-assisted therapies—specifically psilocybin and ibogaine—could help treat addiction and mental health conditions such as depression and trauma. It emphasizes that, while potential benefits are real, online narratives often ignore risks and clinical nuance.

Key Points and Arguments

1) “Myth vs fact” framing: risks are real, even if overall profiles differ

Psilocybin: “high dose traps you forever” myth

• Claims that a high dose can permanently “trap” someone in a trip are addressed by the host and Dr. Thomas.
• Dr. Thomas agrees that permanent trapping is unlikely, but notes that longer-lasting negative effects can occur—especially in vulnerable individuals (e.g., those predisposed to psychosis or related conditions).
• She points to research on challenging experiences.

Ibogaine: “it just replaces one dangerous opioid with another” myth

• A common claim is that ibogaine “replaces” one dangerous addictive drug with another.
• Dr. Thomas argues this is mechanistically different from opioid relapse dynamics and is therefore not a fair comparison.

Relative life-threatening risk myth

• Dr. Thomas states that ibogaine has higher risk of potentially life-threatening side effects during a session compared with psilocybin.
• She highlights cardiotoxic concerns that require continuous monitoring, such as:
  • rhythm changes
  • possible cardiac arrest

Escapism myth

• The video discusses risks when psychedelics are used without intention or a proper container (e.g., “tuning out” reality).
• Dr. Thomas stresses that intentionality and a therapeutic framework matter.
• Repeated high-dose use can create a preference for “out there” experiences over “here.”

“One dose cures” myth

• Dr. Thomas rejects claims that a single supervised dose cures depression or addiction without further mental or behavioral change.
• While profound shifts can happen, she argues recovery is typically more complex and requires ongoing work.

2) Psilocybin research: promising effects, but not a simplistic “therapy package”

• Dr. Thomas describes her work in psilocybin trials at the University of Wisconsin–Madison, including early pharmacokinetic safety research, and her involvement in depression and substance use disorder studies (including methamphetamine and opioid use disorder).
• The research highlights:
  • changes in brain network communication
  • synaptic-related findings discussed in terms of neuroplasticity and “neurogenesis”-adjacent mechanisms
• She also emphasizes that psilocybin sessions are long (approximately 6–8 hours) and can involve identity-level shifts, such as:
  • “life review”
  • meaning-making
  • emotional and experiential processing

What people call “psilocybin therapy” isn’t a single uniform model

• Dr. Thomas clarifies that many people assume a standardized “therapy model,” but regulatory packaging and trial structures differ.
• She notes that FDA-bound programs are moving toward a psychosocial support model, typically including:
  • preparation
  • support during sessions
  • integration afterward
• This may not always resemble a traditional model where a therapist provides continuous therapy during the experience.

Integration is essential

• Integration is described as the bridge between the non-ordinary state and ordinary life.
• It supports internalization of changes and application through behavior and decision-making.
• The video also stresses that integration is often under-discussed.

Disappointment risk

• Because media sometimes portrays psychedelics as miraculous, expectations can become unrealistic.
• When expectations aren’t met, participants may feel frustrated.
• Clinical support includes managing this unpredictability.

3) Evidence expectations for treatment and the regulatory pipeline

• Dr. Thomas explains depression is expected to be the first FDA indication for psilocybin in the near term, with different sponsors studying depression subtypes.
• Other indications being tracked include:
  • nicotine use disorder
  • alcohol use disorder
  • and later-timeline opioid use disorder research
• She also references PTSD research and regulatory developments that enable group settings in New Mexico.

4) Clinical vs non-clinical access: Oregon/Colorado “wellness centers” and standards of support

Beyond clinical trials, the video discusses out-of-trial options and the variability in safety standards:

• Oregon “wellness centers”
  • Facilitator certification may be required
  • Facilitators are not always licensed mental health providers
  • Intake may be more limited than in trials
• Colorado “practitioner-based” models
  • State designation/administration by licensed practitioners

Dr. Thomas’s stance: If people pursue out-of-trial options, they should ask detailed questions about:

• monitoring procedures
• facilitator vs therapist roles
• what happens if things become difficult
• what integration and follow-up are provided

5) Ibogaine: unique mechanism, fewer trials, stronger caution

• Dr. Thomas frames ibogaine as derived from an African shrub with a historical spiritual context.
• However, she emphasizes that clinical evidence is smaller compared with psilocybin.
• She describes a different pharmacology, affecting multiple neurotransmitter systems beyond serotonin, including:
  • glutamate
  • dopamine
  • opioid receptor activity

Mechanism explanation (as presented)

• Ibogaine has affinity at opioid receptor sites.
• Retreat models claim it can help people move out of opioid withdrawal faster.
• Reported effects may last up to around 36 hours in the system (per her description), potentially interrupting the withdrawal/relapse cycle.

Major concern: retreat environments may lack rigorous vetting

• She reports having heard stories of deaths in retreat centers.
• She argues current systems for consumer protection and quality assurance are inadequate.
• She emphasizes the need for better:
  • oversight
  • stewarding roles
  • education
  • complaint-reporting mechanisms

Profound experiences may not prevent relapse

• Even when experiences are intense or transformative, Dr. Thomas warns that without behavior change and integration, people may relapse quickly after leaving retreats.
• She loosely compares this to intense “big-opening” experiences (e.g., intensive training approaches) that may not sustain without ongoing support.

6) Overall message: don’t oversimplify; use ethics and discernment

Dr. Thomas repeatedly warns against claims like “as safe as safe can be.”

Her core recommendations include:

• Keep learning and demand balanced, risk-aware information.
• Seek preparedness through therapy/self-inquiry before any psychedelic encounter.
• Recognize that psychedelic experiences can either help or worsen distress—including cases where individuals report losing mental stability or experiencing persistent symptoms after a difficult exposure.

Presenters / Contributors

• Dr. Shantel Thomas — clinical psychologist, researcher, psychedelic assisted therapy facilitator
• Terry Maguire — host